SMS Lifesciences India Ltd (SMSLIFE) fair value: what the stock is really worth
As of Oct 5, 2026: fair value of SMS Lifesciences India Ltd ₹1,114, price ₹1,549, upside -28.1%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range ₹481.42 – ₹1,744 · fair‑value band ₹742.45 – ₹1,459 · the ₹1,549 price screens above the ₹1,114 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Follow SMS Lifesciences India in your weekly email
Every Wednesday you see whether SMS Lifesciences India is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
SMS Lifesciences India Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers APIs in various therapeutic areas, such as anti ulcer, erectile dysfunction, anti gout, anesthesia, anti infective, anti obesity, antifungal, anti convulsant, anti emetic, ophthalmic, anti worm, and antiemetic.
Show more
SMS Lifesciences India Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers APIs in various therapeutic areas, such as anti ulcer, erectile dysfunction, anti gout, anesthesia, anti infective, anti obesity, antifungal, anti convulsant, anti emetic, ophthalmic, anti worm, and antiemetic. It is also developing APIs in the areas of anti depressant, anti psychotic, anti hypertension, veterinary, antiviral, and anticoagulant. In addition, the company offers intermediates in the anti ulcer, anti migraine, anti hypertension, erectile dysfunction, anti cancer, antifungal, anti obesity, anti emetic, anti depressant, anti worm, anti gout, anti infective, anti convulsant, antiviral, and anesthesia. It also exports its products. SMS Lifesciences India Limited was founded in 1990 and is based in Hyderabad, India.
Stock analysis
SMS Lifesciences India Ltd (SMSLIFE) currently trades at ₹1,549, while our model-based Fair Value estimate is ₹1,114, 28.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹1,237 per share, and 3 of the 24 models we run sit above the ₹1,549 price.
Bear case: the Asset-Based group reads lowest at ₹435.60, and 21 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹742.45 (bear) to ₹1,459 (bull), the price of ₹1,549 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
SMS Lifesciences India Ltd reported revenue of ₹3.4B in FY2025 versus ₹2.6B in FY2021, a compound +6.9%/yr. Reported net income was ₹201M in FY2025, compounding +10.4%/yr from FY2021.
Key figures
Market cap ₹4.7B (≈ $48.6M) · P/E ratio 27.1 · P/S ratio 1.62 · EPS (TTM) ₹57.24 · Dividend yield 0.1% · Net margin 6.0% · Return on equity 9.2% · Return on assets (EBIT) 6.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 41% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −28%, SMSLIFE screens richer than that median.
Fair Value models
Bear ₹742.45Fair Value ₹1,114Bull ₹1,459
Price ₹1,549 · Upside -28.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (₹57.24 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.65/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.7%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+4.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.0%
Dividend (yield on the price)0.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 9%
2025 sits 75% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +15.1% a year for the price.
Compare SMS Lifesciences India Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 607 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score61 · Top 25%
Fair Value upside−28.1% · Above median
Profitability
Return on equity (TTM)9.2% · Top 25%
Return on assets4.8% · Top 25%
Net margin (TTM)5.2% · Above median
Operating margin (TTM)9.6% · Above median
Growth and dividend
Revenue growth−10.9% · Below median
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity0.09× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)27.1× · Pricier than median
P/B2.38× · Pricier than median
P/S (TTM)1.40× · Cheapest 25%
P/FCF25.0× · Pricier than median
EV/EBITDA12.0× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)37· sector 0
HEALTH (low debt)95· sector 97
DIVIDEND (yield)2· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "SMS Lifesciences India Ltd Fair Value". https://www.fairvalue-calculator.com/stock/SMSLIFE
Frequently asked questions
Is SMS Lifesciences India Ltd (SMSLIFE) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of ₹1,114 versus a price of ₹1,549, about −28% upside (overvalued).
What is the fair value of SMSLIFE?
Our model-based fair value for SMS Lifesciences India Ltd is ₹1,114 (as of Oct 3, 2026), built from audited fundamentals. The current price: ₹1,549.
What is the quality score of SMSLIFE?
SMS Lifesciences India Ltd has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SMS Lifesciences India Ltd (SMSLIFE)?
Our model-based price target is the fair value of ₹1,114 (as of Oct 3, 2026) from 24 valuation models. Cautious scenario ₹742.45, optimistic scenario ₹1,459. It is a calculation from audited fundamentals, not an analyst target.
What is the SMS Lifesciences India Ltd stock forecast for 2026?
Our models put fair value at ₹1,114, about −28% upside versus a price of ₹1,549 (overvalued). Cautious scenario ₹742.45, optimistic scenario ₹1,459. The calculation is refreshed regularly with new filings.
What is the revenue of SMS Lifesciences India Ltd (SMSLIFE)?
SMS Lifesciences India Ltd reported trailing-twelve-month revenue of about ₹3.3B (latest available figure, as of Oct 3, 2026).
Does SMS Lifesciences India Ltd pay a dividend?
SMS Lifesciences India Ltd currently shows a dividend yield of about 0.12% relative to its recent price (as of Oct 3, 2026).
What growth is priced into SMS Lifesciences India Ltd (SMSLIFE)?
For today's price to be fair in a discounted-cash-flow model, SMS Lifesciences India Ltd would have to grow free cash flow by +19.8 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.6 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of SMSLIFE use?
Our models discount SMS Lifesciences India Ltd at 10.9 %: a base by market capitalisation (nano), damped by beta 0.31, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SMS Lifesciences India Ltd that is +19.8 % per year a year over ten years, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has SMS Lifesciences India Ltd (SMSLIFE) delivered so far?
Over the past 5 years revenue at SMS Lifesciences India Ltd grew +5.6 % a year. The price currently implies +19.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of SMS Lifesciences India Ltd (SMSLIFE) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into SMS Lifesciences India Ltd (+19.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of SMS Lifesciences India Ltd (SMSLIFE)?
The free-cash-flow yield on the price is 3.99 %: that much free cash flow SMS Lifesciences India Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SMS Lifesciences India Ltd (SMSLIFE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SMS Lifesciences India Ltd it is ₹1,114 per share (as of Oct 3, 2026), against a price of ₹1,549. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is SMS Lifesciences India Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, SMSLIFE trades above its calculated fair value: price ₹1,549, fair value ₹1,114, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SMSLIFE?
No. The price is what the market pays today (₹1,549); the fair value is what the company's own numbers justify (₹1,114). For SMS Lifesciences India Ltd the two are ₹434.94 per share apart. That gap is exactly why we show both numbers side by side.
How much is SMS Lifesciences India Ltd worth?
The market values SMS Lifesciences India Ltd at about ₹4.7B (market capitalisation, as of Oct 3, 2026). Per share that is ₹1,549; our models calculate a fair value of ₹1,114 per share.
What do the bullish and bearish scenarios say about SMSLIFE?
Our models span a range for SMS Lifesciences India Ltd: cautious scenario ₹742.45, base ₹1,114, optimistic ₹1,459 per share (as of Oct 3, 2026, price ₹1,549). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SMSLIFE?
SMS Lifesciences India Ltd trades at a price-to-earnings ratio of 27.1 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹1,114 is built from several models across several years. Other multiples: P/B 2.4, P/S 1.4, EV/EBITDA 12.0.
How solid is the balance sheet of SMS Lifesciences India Ltd (SMSLIFE)?
Balance-sheet figures for SMS Lifesciences India Ltd (as of Oct 3, 2026): return on equity 9.2%, debt of 0.09 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is SMSLIFE from its 52-week high?
SMS Lifesciences India Ltd trades at ₹1,549, about 9% below its 52-week high of ₹1,700 and 41% above the low of ₹1,102 (as of Oct 5, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1,114 is for.
Which stocks are comparable to SMS Lifesciences India Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SMS Lifesciences India Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price ₹1,549, calculated fair value ₹1,114 (−28%), Quality Score 61/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SMSLIFE calculated?
We run SMS Lifesciences India Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹1,114, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. SMS Lifesciences India Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SMS Lifesciences India Ltd (SMSLIFE)?
The closing price on Oct 5, 2026 was ₹1,549. Our model-based fair value is ₹1,114, about −28% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SMS Lifesciences India Ltd right now?
The price sits above even our optimistic bull case (₹1,459). The favourable scenario is already priced in. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹742.45 to ₹1,459) leaves room in how you read the outcome.
Key figures of SMS Lifesciences India Ltd
How large is the market capitalisation of SMS Lifesciences India Ltd (SMSLIFE)?
The market capitalisation of SMS Lifesciences India Ltd is ₹4.7B (≈ $48.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SMS Lifesciences India Ltd (SMSLIFE)?
The price-to-sales ratio of SMS Lifesciences India Ltd is 1.62 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SMS Lifesciences India Ltd (SMSLIFE)?
Earnings per share at SMS Lifesciences India Ltd are ₹57.24 (price ÷ EPS = P/E 27.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of SMS Lifesciences India Ltd (SMSLIFE)?
The dividend yield of SMS Lifesciences India Ltd is 0.1% (payout 3.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SMS Lifesciences India Ltd (SMSLIFE)?
The net margin of SMS Lifesciences India Ltd is 6.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SMS Lifesciences India Ltd (SMSLIFE)?
The return on equity (ROE) of SMS Lifesciences India Ltd is 9.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SMS Lifesciences India Ltd (SMSLIFE)?
On an EBIT basis the return on assets of SMS Lifesciences India Ltd is 6.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SMS Lifesciences India Ltd (SMSLIFE)?
The operating margin of SMS Lifesciences India Ltd is 9.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SMS Lifesciences India Ltd (SMSLIFE)?
Revenue at SMS Lifesciences India Ltd is growing −10.9% versus a year earlier (3y avg −1.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SMS Lifesciences India Ltd (SMSLIFE)?
Earnings per share at SMS Lifesciences India Ltd are growing −40.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does SMS Lifesciences India Ltd (SMSLIFE) carry?
The net debt of SMS Lifesciences India Ltd is ₹835M (fiscal year 2025, ≈ 4.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch SMS Lifesciences India Ltd in the live analysis
One click puts SMS Lifesciences India Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
